Oncology and X-Ray products company
Varian Medical Systems
) recently revealed that a patient with prostate cancer was the
first to receive therapy from the most current edition of
Varian's Vitesse. This offering enables doctors to plan and carry
out the latest high dose rate ("HDR") brachytherapy care, which
is guided by ultrasound. The therapy was provided at the Levine
Cancer Institute in Charlotte, North Carolina.
In HDR brachytherapy, radiotherapy is delivered from within
the anatomy by positioning a small transient radioactive source
within the tumor. Many medical practitioners report a drop in the
quantum of time (in comparison to other forms of treatment)
required to complete the therapy.
Varian is a leading manufacturer of integrated radiotherapy
systems for cancer treatment and a premier supplier of X-Ray
tubes for diagnostic imaging applications. The company operates
in a technology-driven environment where success depends on the
use of new technology, product development and upgrades. In the
radiation oncology market, Varian competes with
The company is poised to increase its market share in
radiation oncology. It currently enjoys a healthy demand for its
coveted TrueBeam technology, which has meaningfully contributed
to its net order oncology growth. Varian's TrueBeam is designed
to treat tumors with beams of high speed and precision. It
incorporates several technological innovations such as patient
positioning and managing his/her motion. Given its high intensity
nature, TrueBeam can dispense strong dosage over twice as fast as
that possible with earlier equipment.
Moreover, Varian continues to post decent results despite the
contagion of economic problems in Europe and sustained softness
in certain end markets. It enjoys a strong balance sheet marked
by low debt and sizeable cash. The company also periodically
deploys capital to boost investor confidence via share
However, Varian competes with larger players in a
technology-intensive industry. Further, uncertainties stemming
from health care reform and a still weak hospital capital
spending environment across many developed countries, especially
in Europe, are significant challenges.
The stock carries a Zacks Rank #3 (Hold).
) are Zacks Rank #1 (Strong Buy) stocks, which are expected to do
ACCURAY INC (ARAY): Free Stock Analysis
CEPHEID INC (CPHD): Free Stock Analysis
CYBERONICS INC (CYBX): Free Stock Analysis
VARIAN MEDICAL (VAR): Free Stock Analysis
To read this article on Zacks.com click here.